PHAT at a glance
Phathom Pharmaceuticals, Inc. (PHAT, SEC CIK 1783183) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 18, 2026 and Form 4 insider filings as recently as October 8, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Phathom Pharmaceuticals, Inc. (PHAT) reported revenue of $175.1 million (up 216.9% from FY2024) and a net loss of $221.2 million. Diluted EPS was -$3.03.
- As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding Phathom Pharmaceuticals, Inc. (PHAT) shares worth $167.2 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $175.1M
- +216.9% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 27 funds
- $167.2M · −2 vs prior quarter
- Latest 8-K
- Nov 18, 2026
- Item 5.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- New litigation risk: BDR challenged FDA’s GAIN Act extension of VOQUEZNA exclusivity through May 3, 2032
- Regulatory risk: adverse ruling could enable earlier ANDA submissions and generic competition
- Market risk: earlier generics could materially reduce VOQUEZNA sales, pricing and market share
- Legal risk: Saba intends to seek consolidation of a related challenge with BDR’s lawsuit
- Operational risk: litigation and FDA proceedings may be lengthy, costly and distracting to management
Management Discussion & Analysis
- Quarterly revenue $84.7M, up $35.2M from $49.5M YoY, driven by VOQUEZNA products
- Gross margin 78.3% vs 87.5% YoY, with cost of revenue $18.4M vs $6.2M
- Net loss $13.9M vs $30.0M YoY, operating loss $0.1M vs $15.3M
- Cash $184.6M; nine-month operating cash outflow $15.7M vs $161.8M YoY
- Outlook: cash and anticipated product revenues sufficient for operations at least twelve months; EoE topline results expected fourth quarter 2026
AI summary of the PHAT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Robert Breedlove resigning as Vice President, Finance and principal accounting officer effective December 4, 2026
- Continued service through December 4 supports near-term transition continuity
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results released for quarter ended September 30, 2026
- Exhibit 99.1 contains the substantive earnings figures and management commentary
Item EX-99.1: Item EX-99.1
- Q3 net revenue $84.7M, up 71% year over year and 14% sequentially, confirming accelerating VOQUEZNA commercialization
- Approximately 380,000 prescriptions filled, including 248,000 covered prescriptions, supporting improving payer access
Item 8.01: Other Events
- FDA opened docket FDA-2026-N-13038 on VOQUEZNA’s exclusivity, with comments due November 23, 2026
- BDR challenges FDA’s recognition of VOQUEZNA’s NCE exclusivity through May 3, 2032
AI summaries of PHAT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for PHAT
Don't miss the next PHAT filing
- Alerts as it files. A push when PHAT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut PHAT, by share count.
- Ask anything. An AI agent that reads every PHAT filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Narula Sanjeev | F | Oct 6, 2026 | 13,485 | $6.78 |
| Breedlove Robert Charles | F | Sep 3, 2026 | 460 | $9.05 |
| Breedlove Robert Charles | F | Jul 14, 2026 | 1,555 | $11.04 |
| Parikh Asit | G | May 22, 2026 | 28,000 | - |
| Parikh Asit | G | May 22, 2026 | 28,000 | - |
| Parikh Asit | M | May 20, 2026 | 17,500 | $4.95 |
| Parikh Asit | D | May 20, 2026 | 17,500 | - |
| KARBE FRANK | A | May 19, 2026 | 24,122 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $55.3M | $175.1M |
| Gross Profit | - | $47.3M | $152.5M |
| Operating Income | - | -$277.5M | -$160.0M |
| Net Income | - | -$334.3M | -$221.2M |
| Gross Margin | - | 85.6% | 87.1% |
| Op. Margin | - | -502.2% | -91.4% |
| Net Margin | - | -605.1% | -126.3% |
| Balance Sheet | |||
| Total Assets | - | $378.3M | $259.1M |
| Equity | - | -$253.6M | -$438.2M |
| ROE | - | 131.8% | 50.5% |
| Per Share | |||
| EPS | $-3.93 | $-5.29 | $-3.03 |
| Cash Flow | |||
| Operating CF | - | -$266.8M | -$166.8M |
| CapEx | $1.6M | $135K | $229K |
Source: XBRL data in Phathom Pharmaceuticals, Inc. (PHAT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate PHAT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 27 | $167.2M |
| Q2 2026 | 29 | $295.9M |
| Q1 2026 | 28 | $278.5M |
| Q4 2025 | 24 | $332.8M |
| Q3 2025 | 22 | $268.4M |
| Q2 2025 | 22 | $182.2M |
| Q1 2025 | 20 | $94.6M |
| Q4 2024 | 17 | $113.7M |
- BlackRock+721.1K (+16%)
- Ameriprise Financial+673.9K (+229%)
- Franklin Resources+435.6K (+22%)
- State Street Corp+411.6K (+26%)
- Citadel Advisors LLC+158.8K (+86%)
- Invesco Ltd−4.00M (-99%)
- Millennium Management−974.9K (-29%)
- Goldman Sachs Group−883.4K (-50%)
- Renaissance Technologies LLC−204.5K (-90%)
- Vanguard Portfolio Management LLC−117.3K (-15%)
- Allstate−32.9K
- FMR LLC (Fidelity)−8.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 189 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
PHAT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 18, 2026 | - | Analysis | - |
| 10-Q | Oct 29, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 29, 2026 | - | Analysis | - |
| 8-K | Oct 26, 2026 | - | Analysis | - |
| 8-K | Oct 23, 2026 | - | Analysis | - |
| 4 | Oct 8, 2026 | - | - | - |
| 8-K | Sep 29, 2026 | - | Analysis | - |
| 4 | Sep 8, 2026 | - | - | - |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 10-Q | Jul 30, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 16, 2026 | - | - | - |
| 8-K | Jun 23, 2026 | - | Analysis | - |
| 4 | May 27, 2026 | - | - | |
| 8-K | May 21, 2026 | - | Analysis | |
| 4 | May 21, 2026 | - | - | |
| 4 | May 21, 2026 | - | - | |
| 4 | May 21, 2026 | - | - | |
| 4 | May 21, 2026 | - | - | |
| 4 | May 21, 2026 | - | - | |
| 4 | May 21, 2026 | - | - | |
| 4 | May 21, 2026 | - | - | |
| 10-Q | Apr 30, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 30, 2026 | - | Analysis | - |
| SC 13G | Mar 12, 2026 | - | - | |
| 4 | Mar 11, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
PHAT SEC filings: frequently asked questions
Which institutions hold PHAT stock?
As of September 30, 2026, the largest Phathom Pharmaceuticals, Inc. (PHAT) holders among the 13F filers tracked by SignalX were BlackRock ($38.3 million), Carlyle Group ($25.5 million), Vanguard Capital Management LLC ($20.0 million), Millennium Management ($17.5 million), State Street Corp ($14.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was PHAT's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Phathom Pharmaceuticals, Inc. (PHAT) reported revenue of $175.1 million (up 216.9% from FY2024) and a net loss of $221.2 million. Diluted EPS was -$3.03. The figures come from the XBRL data in the 10-K.
What did PHAT report in its latest 8-K?
Phathom Pharmaceuticals, Inc. (PHAT) filed an 8-K on November 18, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). Robert Breedlove resigning as Vice President, Finance and principal accounting officer effective December 4, 2026.
What are the latest PHAT SEC filings?
Phathom Pharmaceuticals, Inc. (PHAT) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 18, 2026 and a Form 4 insider filing on October 8, 2026.
What is PHAT's SEC CIK number?
Phathom Pharmaceuticals, Inc. (PHAT)'s SEC Central Index Key (CIK) is 1783183. EDGAR lists every PHAT filing under that number.
Ask anything about PHAT
The research agent reads PHAT's filings, financials, insider trades and 13F holders, then answers with sources.